Biotech Values

[jbog]

A little more from Wedbush

Wedbush reiterates an 'Outperform' rating on Momenta Pharmaceuticals (Nasdaq: MNTA), price target $29.

Wedbush analyst says, "We note that over one month has now passed since approval of MNTA s M-Enox and the FDA has yet to approve a second generic version from the two remaining ANDAs (Teva (Nasdaq: TEVA) & Amphastar). We believe this milestone to be important as we note that some investors were expecting an approval of Teva s generic version one month after M-Enox, due to reports that the immunogenicty data for M-Enox was filed one month earlier than Teva.

Now that this overhang is passing, we believe the threat of a second generic receiving approval in 2010 is diminishing." To see all the upgrades/downgrades on shares of MNTA, visit our Analyst Ratings page. Shares are currently trading at $15.37, up $0.31 (+2.06%) today. The 52-wk range is $8.70 - 26.20.